Studying Amphetamine Withdrawal in Humans

Status Completed

Clinical Trial Summary

Methamphetamine use is very common in the US and is associated with serious medical and psychiatric problems. There has also been a significant increase in the number of patients entering treatment for methamphetamine dependence, however, no pharmacologic treatment has been identified as effective in treating methamphetamine addiction. Given that withdrawal from methamphetamine is thought to contribute to relapse to methamphetamine use during early treatment, it is important to examine potential pharmacologic agents for alleviating withdrawal. Thus, this study is designed to study methamphetamine withdrawal in humans. To this end, 30 methamphetamine dependent participants (ages 18-65 years) will be entered into a 4-week residential study. Urine samples will be obtained at baseline to ensure recent methamphetamine use. Intake assessments will include cognitive testing, standardized assessment of depression and anxiety, profile of mood states, methamphetamine selective severity assessment, methamphetamine withdrawal assessment, sleep quality and quantity, a pre-attentional measure and attentional measure. Upon admission to the residential facility, all study participants will be started on (20-30mg) long acting amphetamine/d-amphetamine and stabilized over the first 5 days. After stabilization participants will be randomized based on sex, amphetamine withdrawal questionnaire score, and methamphetamine selective severity assessment score to either continued treatment with amphetamine/d-amphetamine or placebo for 2 weeks. All subjects will then be placed on placebo for the last 7 days. The investigators hypothesis is that stopping amphetamine administration in methamphetamine dependent individuals will negatively impact mood, sleep and cognitive function in a time-limited fashion that may differ depending upon the measure and that attentional, but not pre-attentional, measures will be adversely affected in those receiving placebo compared to those maintained on amphetamine.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Methamphetamine Dependence

Clinical Trial Details

NCT number	NCT01215929
Study type	Interventional
Source	University of Arkansas
Contact
Status	Completed
Phase	Phase 2
Start date	October 2009
Completion date	May 2014

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01813656` - An Study of Aripiprazole in the Treatment of Methamphetamine Dependence	Phase 4
Completed	`NCT00984360` - Study of Naltrexone for Methamphetamine Addiction	Phase 2
Completed	`NCT01685463` - Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving	N/A
Completed	`NCT00569374` - Safety and Tolerability of Modafinil for Methamphetamine Dependence	Phase 2
Completed	`NCT01967381` - Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse	Early Phase 1
Completed	`NCT01354470` - A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence	Phase 2
Active, not recruiting	`NCT01044238` - Methylphenidate to Treat Methamphetamine Dependence	Phase 2
Terminated	`NCT01019707` - Safety Assessment of Atomoxetine With MA IV Administration	Phase 1
Completed	`NCT00227123` - A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence	N/A
Recruiting	`NCT02568878` - Creatine for Depressed Male and Female Methamphetamine Users	Phase 3
Completed	`NCT01011829` - Varenicline vs Placebo for the Treatment of Methamphetamine Dependence	Phase 2
Completed	`NCT01007539` - Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence	Phase 3
Completed	`NCT01062451` - An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence	Phase 1
Completed	`NCT00687713` - Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence	Phase 2
Completed	`NCT01063205` - NAC as a Potential Treatment for Methamphetamine Dependence	Phase 1
Completed	`NCT02058966` - Pilot Study of Entacapone for Methamphetamine Abuse	Early Phase 1
Completed	`NCT00332605` - N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence	Phase 2
Completed	`NCT01860807` - Trial of Ibudilast for Methamphetamine Dependence	Phase 2
Terminated	`NCT01813643` - A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis	Phase 4
Completed	`NCT01073319` - Rivastigmine as a Treatment for Methamphetamine Dependence	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.